|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-7-25
|
|
pubmed:abstractText |
Integrins alpha v beta 3 and alpha v beta 5 are important in tumor growth and angiogenesis and have been recently explored as targets for cancer therapy. Radiotherapy also inhibits tumor growth and affects vasculature. We explored the combination of integrin antagonist Cilengitide (EMD 121974) and ionizing radiation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1536-43
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16863930-Apoptosis,
pubmed-meshheading:16863930-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16863930-Cell Line, Tumor,
pubmed-meshheading:16863930-Combined Modality Therapy,
pubmed-meshheading:16863930-Endothelial Cells,
pubmed-meshheading:16863930-Endothelium, Vascular,
pubmed-meshheading:16863930-Humans,
pubmed-meshheading:16863930-Integrin alphaVbeta3,
pubmed-meshheading:16863930-Lung Neoplasms,
pubmed-meshheading:16863930-Radiation Tolerance,
pubmed-meshheading:16863930-Snake Venoms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
